CXCL9 and colorectal carcinoma: Similarly, it has been revealed that consensus molecular subtype 1 of CRC characterized by high immune infiltration and activation has high expression of CXCL9, CXCL10, CXCL13, HLA I, HLA II, and immune checkpoint inhibitors [35].